Spriggs D R, Sokal J E, Griffin J, Kufe D W
Cancer Drug Deliv. 1986 Summer;3(3):211-6. doi: 10.1089/cdd.1986.3.211.
Low dose ara-C has been widely used in the treatment of preleukemia and leukemia. These studies have generally utilized either a twice daily, subcutaneous bolus schedule or a continuous intravenous infusion schedule. In order to surmount the logistical problems of long term intravenous infusion while providing prolonged ara-C exposure, we have studied the pharmacology of administering ara-C (20 mg/M2/d) by continuous subcutaneous infusion. The results obtained in eight patients demonstrate that steady state plasma ara-C levels achieved during continuous subcutaneous infusion (24.6-65.6 nM) are not significantly different than those obtained during intravenous infusions (26.2-61.5 nM). Subcutaneous infusions result in prolonged myelosuppression similar to that seen with continuous intravenous infusions. The continuous infusion of low dose ara-C by the subcutaneous route provides a treatment option for some outpatients and offers advantages over intravenous infusions which often require placement of venous catheters or hospitalization.
小剂量阿糖胞苷已广泛应用于白血病前期和白血病的治疗。这些研究通常采用每日两次皮下推注方案或持续静脉输注方案。为了克服长期静脉输注的后勤问题，同时提供延长的阿糖胞苷暴露时间，我们研究了通过持续皮下输注给予阿糖胞苷（20mg/M²/天）的药理学。在8名患者中获得的结果表明，持续皮下输注期间达到的稳态血浆阿糖胞苷水平（24.6 - 65.6nM）与静脉输注期间获得的水平（26.2 - 61.5nM）无显著差异。皮下输注导致的骨髓抑制延长，与持续静脉输注所见相似。通过皮下途径持续输注小剂量阿糖胞苷为一些门诊患者提供了一种治疗选择，并且比通常需要放置静脉导管或住院的静脉输注具有优势。
